Juan J. Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juan J. Gonzalez has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Menéndez
Technological University of Havana Jose Antonio Echeverria. CETER. 114 Street #11901 ZIP 19390, Havana, Cuba
1 shared publication - Alejandro Sotillo
University of Strasbourg, CNRS, LIVE UMR 7362, Strasbourg, France
1 shared publication - Andrés Esteban-Cantos
Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
1 shared publication Art- Pro
1 shared publication- Asunción Hernando
European University of Madrid
1 shared publication - Belén Alejos
Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain
1 shared publication
Latest Publications
- 17 November 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (3) , 738-742
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study
Background: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. Objectives: To present 96 week results from ART-PRO. Methods: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. Results: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. Conclusions: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.
- 17 November 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (3) , 738-742
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study
Background: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. Objectives: To present 96 week results from ART-PRO. Methods: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. Results: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. Conclusions: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.
- 1 January 2018
- Published by Begell House Inc. Publishers
- p. 429-441
HEAT TRANSFER ENHANCEMENT IN A HEAT EXCHANGER HAVING TWO ROWS OF ROUND TUBES AND SLIT FINS USING VORTEX GENERATORS
Compact heat exchangers with just a few rows of tubes are frequently used in the air conditioning and refrigeration industry. The trend at this moment aims to build surfaces with a higher thermo-hydraulic performance, looking to reduce the heat exchange areas and lowering costs during the production process. This paper is about the enhancement of heat transfer in a slit fin having two rows of tubes in a staggered array. A passive enhancement technique using vortex generators was used. The vortex generators location is investigated and the best one among the studied is found. The best location of vortex generators produces a thermal performance higher than the slit fin in smooth condition ranging from 4.9% to 12.35%. On the other hand, the pressure drop was increased up to 22.4%. Surfaces in smooth conditions and using vortex generators are compared using the "volume goodness factor" resulting in a positive effect of vortex generators on the slit fin surface. Vortex generators of Delta Winglet type with a unitary aspect ratio are used. The flow and temperature fields are investigated to explain local results. The study was made inside the laminar regime using Computational Fluid Dynamics. The numerical method is validated against published experimental results and almost a perfect match was found. All results presented in this paper were obtained from independent mesh solutions.
- 1 January 2018
- Published by Begell House Inc. Publishers
- p. 429-441
HEAT TRANSFER ENHANCEMENT IN A HEAT EXCHANGER HAVING TWO ROWS OF ROUND TUBES AND SLIT FINS USING VORTEX GENERATORS
Compact heat exchangers with just a few rows of tubes are frequently used in the air conditioning and refrigeration industry. The trend at this moment aims to build surfaces with a higher thermo-hydraulic performance, looking to reduce the heat exchange areas and lowering costs during the production process. This paper is about the enhancement of heat transfer in a slit fin having two rows of tubes in a staggered array. A passive enhancement technique using vortex generators was used. The vortex generators location is investigated and the best one among the studied is found. The best location of vortex generators produces a thermal performance higher than the slit fin in smooth condition ranging from 4.9% to 12.35%. On the other hand, the pressure drop was increased up to 22.4%. Surfaces in smooth conditions and using vortex generators are compared using the "volume goodness factor" resulting in a positive effect of vortex generators on the slit fin surface. Vortex generators of Delta Winglet type with a unitary aspect ratio are used. The flow and temperature fields are investigated to explain local results. The study was made inside the laminar regime using Computational Fluid Dynamics. The numerical method is validated against published experimental results and almost a perfect match was found. All results presented in this paper were obtained from independent mesh solutions.
- 1 January 1991
- Published by Wiley in Acta Hydrochimica et Hydrobiologica
- Vol. 19 (6) , 703-709
Biodegradability and Toxicity of Anionic Surfactants
Alkyl sulphates of the general formula CH2n + 1‐O‐SO3Na and alkyl sulphonates of the general formula CnH2n + 1‐SO3Na, where n = 8, 10, 12, 14 in each series have been tested for biodegradability with the modified OECD screening test No. 301 E, and for toxicity with Daphnia magna and with Photobacterium phosphoreum (the MicrotoxTM test). The results show that both alkyl sulphates and alkyl sulphonates are biodegraded with the alkyl sulphates degrading more rapidly under the test conditions. The alkyl sulphates also have higher toxicity to both test species and for both alkyl sulphates and sulphonates the toxicity increases linearly with increasing molecular weight of the surfactant.
- 1 January 1991
- Published by Wiley in Acta Hydrochimica et Hydrobiologica
- Vol. 19 (6) , 703-709
Biodegradability and Toxicity of Anionic Surfactants
Alkyl sulphates of the general formula CH2n + 1‐O‐SO3Na and alkyl sulphonates of the general formula CnH2n + 1‐SO3Na, where n = 8, 10, 12, 14 in each series have been tested for biodegradability with the modified OECD screening test No. 301 E, and for toxicity with Daphnia magna and with Photobacterium phosphoreum (the MicrotoxTM test). The results show that both alkyl sulphates and alkyl sulphonates are biodegraded with the alkyl sulphates degrading more rapidly under the test conditions. The alkyl sulphates also have higher toxicity to both test species and for both alkyl sulphates and sulphonates the toxicity increases linearly with increasing molecular weight of the surfactant.